Drug Trial Radar · NCT03516981
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
245
Actual
Start
Oct 1, 2018
Primary completion
Jun 13, 2025
Study completion Jun 13, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile \[GEP\] and tumor mutational burden \[TMB\]) will be randomized to receive pembrolizumab in combination with quavonlimab (MK-1308), favezelimab (MK-4280), or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either quavonlimab, favezelimab, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.
Conditions
- Advanced Non-Small Cell Lung Cancer
Interventions
PembrolizumabBiological
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
FavezelimabBiological
200 mg or 800 mg favezelimab solution for IV infusion administered Q3W
LenvatinibDrug
20 mg lenvatinib capsules administered orally once daily
QuavonlimabDrug
Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to approximately 80 months
Locations
81 sites in 16 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates, PC- HAL ( Site 8001)
Tempe, Arizona
University of California Davis Comprehensive Cancer Center ( Site 0137)
Sacramento, California
University of California San Francisco ( Site 0111)
San Francisco, California
UCLA Hematology/Oncology -Santa Monica ( Site 0108)
Santa Monica, California
Yale University School of Medicine ( Site 0100)
New Haven, Connecticut
Mayo Clinic Florida ( Site 0115)
Jacksonville, Florida
University of Maryland ( Site 0136)
Baltimore, Maryland
Mayo Clinic Rochester - St. Mary's Hospital ( Site 0117)
Rochester, Minnesota
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0112)
Hackensack, New Jersey
Memorial Sloan Kettering Cancer Center ( Site 0113)
New York, New York
Weill Cornell Medical College ( Site 0138)
New York, New York
Oncology Hematology Care ( Site 8005)
Cincinnati, Ohio
University of Pennsylvania ( Site 0132)
Philadelphia, Pennsylvania
UPMC Cancer Center/Hillman Cancer Center ( Site 0104)
Pittsburgh, Pennsylvania
Texas Oncology-Memorial City ( Site 8006)
Houston, Texas
Texas Oncology-Tyler ( Site 8003)
Tyler, Texas
Emily Couric Clinical Cancer Center ( Site 0134)
Charlottesville, Virginia
Northwest Cancer Specialists, P.C. ( Site 8000)
Vancouver, Washington
University of Wisconsin- Madison Carbone Cancer Center ( Site 0130)
Madison, Wisconsin
Blacktown Hospital Western Sydney Local Health District ( Site 0200)
Blacktown, New South Wales, Australia
Gallipoli Medical Research Foundation ( Site 0202)
Brisbane, Queensland, Australia
Fiona Stanley Hospital ( Site 0201)
Murdoch, Western Australia, Australia
The Ottawa Hospital ( Site 0306)
Ottawa, Ontario, Canada
Sunnybrook Health Science Centre ( Site 0304)
Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0309)
Toronto, Ontario, Canada
CIUSSS du Saguenay-Lac-St-Jean ( Site 0305)
Chicoutimi, Quebec, Canada
Jewish General Hospital ( Site 0307)
Montreal, Quebec, Canada
CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0310)
Montreal, Quebec, Canada
Prince of Wales Hospital ( Site 1801)
Hong Kong, Hong Kong
Queen Mary Hospital ( Site 1800)
Hong Kong, Hong Kong
St James Hospital ( Site 2200)
Dublin, Ireland
Mid Western Cancer Centre ( Site 2201)
Limerick, Ireland
Azienda Ospedaliera Papardo ( Site 0706)
Messina, Italy
Seconda Universita degli Studi di Napoli ( Site 0704)
Naples, Italy
Fondazione Policlinico Universitario A. Gemelli ( Site 0703)
Roma, Italy
Azienda Ospedaliera Universitaria Senese ( Site 0705)
Siena, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0702)
Meldola, Emilia-Romagna, Italy
Istituto Clinico Humanitas Research Hospital ( Site 0700)
Rozzano, Lombardy, Italy
AOU San Luigi Gonzaga di Orbassano ( Site 0707)
Orbassano, Torino, Italy
AULSS21 Regione Veneto Ospedale Mater Salutis - Legnago ( Site 0701)
Legnago, Verona, Italy
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.